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Hospital and Research Center, P3354, MBC-03, Riyadhp38 mitogen-activated protein kinase (MAPK) stabilises pro-inﬂammatory mediator mRNAs by
inhibiting AU-rich element (ARE)-mediated decay. We show that in bone-marrow derived murine
macrophages tristetraprolin (TTP) is necessary for the p38 MAPK-sensitive decay of several
pro-inﬂammatory mRNAs, including cyclooxygenase-2 and the novel targets interleukin (IL)-6, and
IL-1a. TTP/ macrophages also strongly overexpress IL-10, an anti-inﬂammatory cytokine that
constrains the production of the IL-6 despite its disregulation at the post-transcriptional level. TTP
directly controls IL-10 mRNA stability, which is increased and insensitive to inhibition of p38 MAPK
in TTP/macrophages. Furthermore, TTP enhances deadenylation of an IL-10 30-untranslated region
RNA in vitro.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Circumstantial evidence suggests that the p38 MAPK pathwayThe presence of an AU-rich element (ARE) in the 30-untranslated
region (UTR) of a large number of mRNAs causes them to be highly
unstable. Many ARE-containing mRNAs of the inﬂammatory re-
sponse are stabilised following activation of p38 mitogen-activated
protein kinase (MAPK) [1]. Tristetraprolin (TTP) regulates the
expression of tumour necrosis factor (TNF) by binding the ARE in
the 30UTR of TNF mRNA and targeting it for degradation [2]. TTP
knockout mice develop a complex inﬂammatory phenotype and
display inﬂammatory arthritis, cachexia, conjunctivitis and mye-
loid hyperplasia caused by increased TNF production [3]. TTP also
regulates granulocyte-macrophage colony-stimulating factor [4],
interleukin (IL)-2 [5], immediate-early response gene 3 [6], IL-10
[7] and chemokine (C-X-C) ligand 1 (CXCL1) [8] mRNA stability.chemical Societies. Published by E
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earch, King Faisal Specialist
11211, Saudi Arabia.regulates mRNA stability by inactivating TTP. TTP promotes mRNA
deadenylation [4,9], whereas p38 MAPK inhibits it [10] and TTP is a
substrate of the kinase downstream of p38 MAPK, MAPK-activated
protein kinase 2 (MK2) [11]. Blockade of TNF biosynthesis by p38
MAPK inhibition was shown to be impaired in TTP/ cells [12].
More directly, it was shown that post-transcriptional regulation
of TNF [13] and CXCL1 [8] expression by the p38 MAPK pathway
is TTP-dependent. However, other RNA-binding proteins such as
HuR and KSRP have also been implicated as mediators of post-tran-
scriptional responses to p38 MAPK [1,14]. It is therefore unclear to
what extent TTP is responsible for post-transcriptional effects of
p38 MAPK during an inﬂammatory response. To answer this ques-
tion we investigated post-transcriptional regulation of several
mediators of the inﬂammatory response in wild-type and TTP/
macrophages stimulated with lipopolysaccharide (LPS).2. Materials and methods
2.1. Materials
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imid-
azole (SB 202190), LPS (Salmonella typhimurium) and [a-32P]-UTP
were from Calbiochem-Novabiochem, Sigma–Aldrich and GElsevier B.V. All rights reserved.
1934 C. Tudor et al. / FEBS Letters 583 (2009) 1933–1938Healthcare, respectively. Anti-IL-10, anti-COX-2 and anti-a-tubulin
antibodies were from R&D systems, Alexis and Sigma–Aldrich
respectively. Details of riboprobe templates and IL-10 30UTR
in vitro deadenylation assay and BBB IL-10 30UTR plasmids are
available upon request.
2.2. Mice
TTP/ mice were originally generated previously [3]. TTP/
mice were of mixed 129 and C57BL/6 background as originally
obtained from Perry Blackshear. All animal experiments were
performed according to ethical procedures.
2.3. Bone marrow-derived macrophage (BMDM) preparation
TTP/ and wild-type littermate mice were humanely culled
and bone marrow was extracted. Macrophages were derived by
differentiation with L929-cell conditioned medium or macrophage
colony stimulating factor (PeproTech) [13].
2.4. mRNA measurements
Total RNA was isolated from BMDM using a QIAamp kit (Qia-
gen). TNF, cyclooxygenase-2 (COX-2) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNAs were analysed by
northern blotting as described previously [10]. IL-10 (and GAPDH)
mRNA was measured by quantitative RT-PCR (see Supplementary
data for details). Other endogenous mRNAs were quantiﬁed using
a ribonuclease protection assay kit and mCK-2b template set (BD
Biosciences). Analysis of reporter mRNA stability was performed
by ribonuclease protection assay as described previously [10].
2.5. Enzyme-linked immunosorbent assay (ELISA) and Western
blotting
ELISAs for IL-6 and TNF (R&D systems), IL-10 (BD Biosciences),
IL12p40 (EBioscience) were performed according to the manufac-
turer’s instructions. Western blotting was performed according to
standard procedures.
2.6. Electrophoretic mobility shift assay
An RNA oligonucleotide spanning the IL-1a AREwas synthesised
commercially (Dharmacon). The sequence was: GUUAUUUUUAA-
GUUAUUUAUCUAUGUAUUUAUAAUAUAUUUAUGAUAAUUAUAUU-
AUUUAUG. The oligonucleotide was end-labelled with [c-32P]ATP
(3000 Ci/mmol) using T4 polynucleotide kinase. 32P-labelled RNA
probe (approx. 0.1 pmol) was incubated for 15 min at room temper-
ature with 100 ng of GST–TTP or glutathione-S-transferase (GST) in
the absence or presence of a 10-fold excess (1 pmol) of unlabelled
IL-1a or antisense b-globin riboprobe in 20 ll of bandshift buffer
(20 mM HEPES, pH 7.2, 100 lM ZnCl2, 50 mM KCl, 1 mM DTT, 5%
glycerol) containingheparin sulfate (5 mg/ml).Unlabelled antisense
b-globin riboprobe [4] was prepared by in vitro transcription by
standard methods and quantiﬁed by Nanodrop. Two microlitres of
loading buffer (80% glycerol, 0.1% bromophenol blue) was then
added and RNA–protein complexes were resolved by electrophore-
sis on a 4% (w/v) acrylamide/Tris–borate gel using Tris–borate run-
ning buffer. Complexes were visualised using a phosphorimager
(FLA5000; Fuji). The image shownwas gamma corrected to improve
the contrast in order to visualise complexes more clearly.
2.7. In vitro deadenylation assay
This was performed similarly to Lai et al. [9] (see Supplemen-
tary data).3. Results
3.1. p38 MAPK stabilises mRNAs of the inﬂammatory response by
inactivation of TTP
To investigate whether p38 MAPK-mediated inhibition of TTP-
directed decay represents amore general mechanism than that cur-
rently suggested [8,13], the stability of several p38MAPK-regulated
mRNAs was examined by actinomycin (Act) D chase in LPS-treated
wild-type and TTP/ bone marrow-derived macrophages (BMDM)
in the presence or absence of p38 MAPK blockade. IL-10 mRNAwas
also examined as it contains an ARE and is a recently identiﬁed TTP
target [7]. In wild-type cells there was little decay of IL-10, COX-2,
IL-6, and IL-1amRNAs in the absence of SB 202190 (Fig. 1 and Table
1) but addition of the inhibitor resulted in their rapid destabilisa-
tion (Fig. 1 and Table 1). The inhibitor had no effect on the stability
of thesemRNAs in TTP/ BMDM (Fig. 1 and Table 1). Similar results
were obtained for TNF mRNA (Table 1). This was independently
conﬁrmed by pre-treatment of cells with SB 202190 1 h prior to
LPS stimulation (to block TTP expression) for 4 h followed by acti-
nomycin D (Act D) chase or by simultaneously adding the inhibitor
with Act D (Fig. 1I).
In LPS-treated TTP/ cells in the absence of SB 202190 the stabil-
ity of IL-10mRNAwas 2.5-fold greater than in wild-type cells (Fig. 1
andTable 1), conﬁrming it as a TTP target [7]. SB202190displays rel-
atively good speciﬁcity at the 1 lM concentration used (Fig. 1A–H).
Nevertheless, the novel p38 MAPK-mediated stabilisation of IL-10
mRNA was conﬁrmed using a tetracycline-regulated reporter sys-
tem [10] (Fig. 2). Active mutants of MKK6, a p38 MAPK activator,
and MK2 stabilised an IL-10 30UTR reporter mRNA (Fig 2).
IL-12p40, IL-1b, IL-1 receptor antagonist, macrophage inhibitory
factor, L32 and GAPDH mRNA half-lives were unaffected by
SB202190 treatment in wild-type and TTP/ BMDM (data not
shown). Overall, these results show that p38 MAPK-mediated inhi-
bition of TTP-directed mRNA decay represents a common mecha-
nism for six (including previously published CXCL1 [8]) different
mRNAs of the inﬂammatory response. IL-1a mRNA was shown to
be a direct target of TTP by electrophoretic mobility shift assay
(Fig. 2E).3.2. Expression of inﬂammatory response mRNAs and proteins in wild-
type and TTP/ BMDM
To investigate whether TTP regulates the expression of its tar-
gets, inﬂammatory response mRNAs and proteins were measured
in unstimulated wild-type and TTP/ macrophages and at 4 h
post-LPS. LPS-treated TTP/ BMDM expressed 5-fold more IL-10
mRNA (Fig. 3A) and 4-fold more protein (Fig. 3B) than wild-type
cells. TNF and COX-2mRNA and protein expression was also upreg-
ulated in LPS-treated TTP/ BMDM (Fig. 3A, B and C) as reported
previously [3,15]. Surprisingly, LPS-induced IL-6 mRNA and protein
expression was inhibited in TTP/ cells (Fig. 3A and B). IL-12p40
mRNA and protein expression induced by LPS was also reduced in
TTP/ cells (Fig. 3A and B). IL-1a mRNA was unchanged (Fig. 3A).
There was no signiﬁcant difference in inﬂammatory mediator
expression in unstimulated wild-type and knockout cells. Of the
mediators examined, IL-10 was most strongly upregulated in LPS-
treated TTP/ BMDM suggesting an important role for TTP in regu-
lating its expression.3.3. IL-10 blockade rescues IL-6 and IL-12p40 production in TTP/
BMDM
Since it could be possible that the reduction in IL-6 and IL-
12p40 protein in TTP/ BMDM is due to increased production of
Fig. 1. Regulation of inﬂammatory response mRNA stability by p38 MAPK requires TTP. Wild-type (A, C, E, G) or TTP/ (B, D, F, H) BMDMwere treated with LPS (10 ng ml1)
for 4 h and then Act D (10 lg ml1) was added together with SB 202190 (ﬁnal concentration 1 lM) or vehicle (0.1% DMSO). Cells were harvested at the times shown and RNA
isolated and mRNA measured (see materials and methods). Graphs showmean inﬂammatory response mRNA in wild-type (A, C, E, G) or TTP/ cells (B, D, F, H) normalised to
GAPDH mRNA expressed as a percentage of t = 0 Act D treatment ± S.E.M. from at least three independent experiments. Where not shown error bars are smaller than the
symbols. Signiﬁcance was determined by paired Student’s t-test *p < 0.05; **p < 0.01; ***p < 0.001. (I) Act D chase for TNF mRNA in wild-type BMDM as above, but with 1 lM
SB 202190 added simultaneously with Act D at 4 h, or 5 lM SB 202190 added at 1 h prior to LPS stimulation to block TTP expression. Representative of two independent
experiments.
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Table 1
Stability of mRNAs in wild-type and TTP/ BMDM in the presence or absence of p38
MAPK inhibitor. Half-lives (t1/2) of initial decay were calculated for t = 0  60 min
post-Act D.
mRNA Wild-type BMDM TTP/ BMDM
t1/2(DMSO) (min) t1/2(SB) (min) t1/2(DMSO) (min) t1/2 (SB) (min)
IL-10 50 ± 16 14 ± 0.3 127 ± 19 111 ± 36
COX-2 128 ± 44 43 ± 8 >300 >300
IL-6 62 ± 12 26 ± 5 301 277
IL-1a >300 65 ± 15 >300 247
TNF 44 ± 5 15 ± 1 87 ± 5 55 ± 2
1936 C. Tudor et al. / FEBS Letters 583 (2009) 1933–1938IL-10, IL-10 was neutralised with an antibody raised against it. Six-
teen hours LPS treatment resulted in a greater difference in TNF
expression between wild-type and TTP/ BMDM (Fig. 3D) com-
pared with 4 h stimulation (Fig. 3B). Pre-treatment of cells with
anti-IL-10 prior to LPS increased TNF to a similar degree in theFig. 2. Active mutants of MKK6 and MK2 stabilise an IL-10 30UTR reporter mRNA and TTP
10 30UTR reporter and MKK6E or MK2EE expression plasmids. After 24 h doxycycline
measured by RPA. (A and C) Phosphorimages of RPAs. Plots of mean normalised mRNA an
timepoints (D). (E) 32P end-labelled IL-1a ARE RNA probe (0.1 pmol) was incubated with
self or N.S. (non-self) competitor RNAs. RNA–protein complexes were resolved by electr
probe and the TTP-RNA complexes are indicated. Four clear complexes are visible, consist
three experiments.two cell types (Fig 3D). It also increased IL-6 production in wild-
type cells, and completely restored IL-6 expression in TTP/ cells
(Fig. 3E). Similar results were obtained for IL-12p40 (Fig. 3F). Thus
the reduced expression of IL-6 and IL-12p40 in TTP/ BMDM can
be attributed to increased production of IL-10 arising from TTP
deﬁciency. It is noted that IL-1a mRNA, which is also known to
be regulated by IL-10 was inhibited in TTP/ BMDM at 20 h
post-LPS (data not shown).
3.4. TTP directs deadenylation of an IL-10 RNA substrate in vitro
To investigate how TTP regulates IL-10 mRNA decay, an in vitro
deadenylation assay was performed using HeLa cell S100, GST–TTP,
and 32P-labelled RNA substrates containing portions of the IL-10
30UTR with poly(A) tails of 100 nucleotides. Three IL-10 RNA
substrates were used: nucleotides 601–739 (no AUUUA motifs),
739–920 (5 AUUUAs) and 920–1295 (1 AUUUA motif) of the IL-10binds speciﬁcally to the IL-1a ARE. HeLa tet-off cells were transfected with BBB-IL-
was added to block transcription and BBB-IL-10 30UTR and GAPDH mRNAs were
d S.E.M. for three experiments (B) or representative of 3 experiments with different
GST–TTP (100 ng) or GST (100 ng) in the absence or presence of 1 pmol of unlabelled
ophoresis and visualised using a phosphorimager. The bands representing the free
ent with multiple TTP binding sites in the IL-1a 30UTR. The result is representative of
Fig. 3. Inﬂammatory response mRNA and protein expression in wild-type and TTP/ BMDM in the absence or presence of IL-10 neutralisation: (A) Wild-type and TTP/
BMDM were treated with LPS for 4 h and inﬂammatory response mRNAs (A) were measured as in Fig. 1, and proteins (B and C) by ELISA and Western blotting, respectively.
(A) Graph shows mean fold-induction of inﬂammatory response mRNAs normalised to GAPDH in TTP/ relative to wild-type BMDM for 3 independent experiments. Dotted
line indicates that expression is the same in wild-type and TTP/ cells. (B) Graph of inﬂammatory response proteins for (A). (D–F) Cells were either left untreated, or pre-
treated with an anti-IL-10 antibody for 1 h and then incubated for a further 16 h in the presence of LPS. TNF (D), IL-6 (E) and IL-12p40 (F) in culture medium was measured by
ELISA.
Fig. 4. TTP directs deadenylation of an IL-10 RNA in vitro. (A) Radiolabelled poly-(A) RNA substrates were produced by in vitro transcription and incubated with 5 lg HeLa
S100 in the presence or absence of 100 ng of GST–TTP for the times shown. Representative phosphorimages and graphs of mean and S.E.M. for three experiments are shown.
In the ﬁnal lanes RNA substrates were deadenylated by treatment with oligo(dT) and RNaseH. The positions of poly-(A)100 and poly-(A)0 bands are indicated. (B) Schematic
of IL-10 30UTR showing AUUUA pentamers (P1–6).
C. Tudor et al. / FEBS Letters 583 (2009) 1933–1938 193730UTR. Addition of GST–TTP resulted in rapid decay of IL-10 30UTR
739–920 RNA but had no effect on the decay of the other two sub-
strates (Fig. 4). The decay of IL-10 30UTR 739-920 in the presence of
TTP was accompanied by the appearance of a higher mobility inter-mediate. It migrated to a similar position to a poly(A)-lacking tran-
script, consistent with it being a deadenylated intermediate. Hence,
TTP recognises the central (ARE-containing) portion of IL-10 mRNA
to target it for deadenylation.
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We show that p38 MAPK-mediated inhibition of TTP-directed
decay represents a more general mechanism for mRNAs of the
inﬂammatory response in BMDM than previously suggested. We
conﬁrm that TTP plays an important role in regulating IL-10 since
steady-state IL-10 mRNA and IL-10 protein were found to be
upregulated in LPS-treated TTP/ BMDM and an IL-10 RNA was di-
rectly regulated by TTP in vitro. p38 MAPK not only regulates cyto-
kine expression at the post-transcriptional level but also
upregulates transcription. Regulation of IL-10 transcription by
p38 MAPK has been shown to involve Sp1 [16] and the down-
stream kinases MSK1 and MSK2 that phosphorylate CREB [17].
These kinases also regulate TTP mRNA production [18].
Since many of the mRNAs examined were relatively stable in
the absence of inhibitor in both wild-type and TTP/ cells, the
employment of p38 MAPK inhibitor in Act D chases revealed tar-
gets of TTP which would otherwise not have been identiﬁed. This
could explain why of the mRNAs found to be regulated by TTP
and p38 MAPK in this study, only IL-10 and TNF have previously
been identiﬁed as TTP targets.
In a recent report describing p38a MAPK-depleted macro-
phages, no effect on inﬂammatory mediator mRNA stability was
observed [19]. This is probably because p38 MAPK activity is
needed for both, the induction of TTP by LPS [11] and subsequent
mRNA decay, since pre-treatment of macrophages with p38 MAPK
inhibitor prior to stimulation with LPS fails to destabilise TNF
mRNA. Given the recent failure of p38 MAPK inhibitors in clinical
trials, TTP and MK2 now represent important downstream targets
for therapies aimed at treating chronic inﬂammatory diseases such
as rheumatoid arthritis. Ideally, such therapies would speciﬁcally
block the expression of pro-inﬂammatory mediators, such as
TNF, whilst sparing anti-inﬂammatory IL-10. Since the same
post-transcriptional mechanism regulates pro-inﬂammatory medi-
ator mRNAs and anti-inﬂammatory IL-10 mRNA, the utility of
MK2- and TTP-targeted therapies aimed at treating chronic inﬂam-
matory diseases may depend on the speciﬁc contribution of these
cytokines to the disease.Acknowledgements
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